Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study
Open Access
Abstract
Objective To determine whether patients taking formulations of drugs that contain sodium have a higher incidence of cardiovascular events compared with patients on non-sodium formulations of the same drugs. Design Nested case-control study. Setting UK Primary Care Patients registered on the Clinical Practice Research Datalink (CPRD). Participants All patients aged 18 or over who were prescribed at least two prescriptions of sodium-containing formulations or matched standard formulations of the same drug between January 1987 and December 2010. Main outcome measures Composite primary outcome of incident non-fatal myocardial infarction, incident non-fatal stroke, or vascular death. We performed 1:1 incidence density sampling matched controls using the UK Clinical Practice Research Datalink (CPRD). For the secondary analyses, cases were patients with the individual components of the primary study composite endpoint of hypertension, incident heart failure, and all cause mortality. Results 1 292 337 patients were included in the study cohort. Mean follow-up time was 7.23 years. A total of 61 072 patients with an incident cardiovascular event were matched with controls. For the primary endpoint of incident non-fatal myocardial infarction, incident non-fatal stroke, or vascular death the adjusted odds ratio for exposure to sodium-containing drugs was 1.16 (95% confidence interval 1.12 to 1.21). The adjusted odds ratios for the secondary endpoints were 1.22 (1.16 to 1.29) for incident non-fatal stroke, 1.28 (1.23 to 1.33) for all cause mortality, 7.18 (6.74 to 7.65) for hypertension, 0.98 (0.93 to 1.04) for heart failure, 0.94 (0.88 to 1.00) for incident non-fatal myocardial infarction, and 0.70 (0.31 to 1.59) for vascular death. The median time from date of first prescription (that is, date of entry into cohort) to first event was 3.92 years. Conclusions Exposure to sodium-containing formulations of effervescent, dispersible, and soluble medicines was associated with significantly increased odds of adverse cardiovascular events compared with standard formulations of those same drugs. Sodium-containing formulations should be prescribed with caution only if the perceived benefits outweigh these risks.Keywords
This publication has 21 references indexed in Scilit:
- The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillationThrombosis and Haemostasis, 2013
- Validation and validity of diagnoses in the General Practice Research Database: a systematic reviewBritish Journal of Clinical Pharmacology, 2009
- Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant HypertensionHypertension, 2009
- Potential Societal Savings from Reduced Sodium Consumption in the U.S. Adult PopulationAmerican Journal of Health Promotion, 2009
- Blood pressure reduction in hypertensive patients after withdrawal of effervescent medicationPharmacoepidemiology and Drug Safety, 2009
- Adverse Cardiovascular Effects of Acute Salt Loading in Young Normotensive IndividualsHypertension, 2008
- Sodium Intake and Mortality in the NHANES II Follow-up StudyThe American Journal of Medicine, 2006
- The way I see it: House officers need formal career developmentBMJ, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group.BMJ, 1988